Experts disagree with controversial BMJ support for older HIV drugs in pregnancy
Polly Clayden, HIV i-Base
Two expert groups have announced that they do not support BMJ Rapid Recommendations favouring a zidovudine and lamivudine-based ART regimen over one that includes tenofovir and emtricitabine in HIV positive pregnant women.
On 21 September 2017, BMJ Open published a controversial analysis and accompanying clinical practice guideline on ART in HIV positive women concluding with low certainty evidence that: “tenofovir/emtricitabine is likely to increase stillbirth/early neonatal death and early premature delivery compared with zidovudine/lamivudine”. [1, 2]